Program
farabursen
In Novartis's pipeline, MIR17 inhibitor
. Its studies are mostly in Polycystic Kidney, Autosomal Dominant, led by Novartis.
Furthest: phase 1, since May 26, 20222 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 20 open or running | phase 1since May 26, 2022 | May 26, 2022 | none ahead |
- Named in Novartis’s own pipeline as
CYX082 (farabursen)
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 26, 2022First study: phase 1 study in Polycystic Kidney, Autosomal DominantFirst studyNCT05429073 · 32 enrolled · United States
- Aug 24, 2022Phase 1 study in Polycystic Kidney, Autosomal DominantNCT05521191 · 68 enrolled · United States
TargetBeta
“MIR17 inhibitor”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05521191Polycystic Kidney, Autosomal Dominant · United States | 1 | Completed | Jan 27, 2025 | 68 |
| NCT05429073Polycystic Kidney, Autosomal Dominant · United States | 1 | Completed | Sep 8, 2022 | 32 |
How it is read
Names in the registry
- “RGLS8429”, 2 entries
Conditions, from the studies’ own filings
- Polycystic Kidney, Autosomal Dominant, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.